Results 161 to 170 of about 476,484 (263)

CXCL10/SLC11A1 Axis Exacerbates Septic Liver Injury by Regulating Neutrophil Extracellular Traps Formation to Drive Macrophage Pro‑Inflammatory Polarization

open access: yesAdvanced Science, EarlyView.
In sepsis‐induced liver injury, marked neutrophil infiltration correlates with disease severity. Neutrophil SLC11A1 drives intracellular Fe2+ and ROS via the Fenton reaction, promoting NETs formation. Hepatocyte‐derived CXCL10 recruits neutrophils and activates the JAK/STAT1/SLC11A1 axis, enhancing NETs‐mediated inflammation.
Haiping Lin   +8 more
wiley   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong   +13 more
wiley   +1 more source

Cobalt Single‐Atom Nanozyme for Enhanced Intestinal Radioprotection and Tumor Radiosensitization via Bidirectional ROS Modulation

open access: yesAdvanced Science, EarlyView.
Orally administered, pH‐responsive Co‐SAN exerts dual functions: in the alkaline intestinal milieu, it scavenges reactive oxygen species (ROS) and suppresses the PI3K/AKT pathway and NETs formation, thus providing radioprotection; whereas in the acidic tumor microenvironment, it generates ROS and alleviates hypoxia, thereby enhancing radiosensitization.
Shengqi Yin   +13 more
wiley   +1 more source

Evaluation of algorithms for predicting new baseline renal function after complex partial nephrectomy for multifocal renal tumors. [PDF]

open access: yesUrol Oncol
Rathi N   +9 more
europepmc   +1 more source

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

open access: yesAdvanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou   +11 more
wiley   +1 more source

Renal angiomyolipoma with inferior vena cava tumor thrombus in a pregnant woman. [PDF]

open access: yesRadiol Case Rep
Shu C   +5 more
europepmc   +1 more source

Microenvironment‐Responsive Nanomedicine Enables Vertical Modulation of Mitochondrial Pathological Networks in Myocardial Ischemia–Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
A mitochondria‐targeted, microenvironment‐responsive nanoplatform enables pH/ROS‐triggered co‐delivery of berberine and isoliensinine to orchestrate ROS scavenging, inflammation suppression, and apoptosis inhibition. This vertical modulation of mitochondrial pathological networks preserves mitochondrial function and effectively mitigates myocardial ...
Jue Wang   +11 more
wiley   +1 more source

Case Report: A case of primary renal synovial sarcoma. [PDF]

open access: yesFront Surg
Li X   +9 more
europepmc   +1 more source

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

open access: yesAdvanced Science, EarlyView.
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy